ICP-OES ELEMENTAL IMPURITY ANALYSIS IN PHARMACEUTICALS

Application Note Pharmaceutical Elemental Impurities in Aspirin: USP <232>/<233> and ICH Q3D Methods Using ICP-OES Validation of the USP <232>/<233> method on an Agilent ICP-OES Author Lindsey Whitecotton, Greg Gilleland, Elizabeth Kulikov, and Amir Liba Agilent Technologies, Inc., USA Samina…

Proposed new ICH and USP methods for elemental impurities: The application of ICP-MS and ICP-OES for pharmaceutical analysis White paper Authors Amir Liba, Ed McCurdy and Ross Ashdown Agilent Technologies Abstract The United States Pharmacopeial Convention (USP), in parallel with…

White Paper USP <232>/<233> and ICH Q3D Elemental Impurities Analysis: The Agilent ICP-OES Solution Elemental Impurity Analysis Requirements Worldwide, regulatory authorities are responsible for ensuring that pharmaceutical products are both effective and safe. To achieve this, potentially harmful contaminants—including elemental…

Measuring Elemental Impurities in Pharmaceutical Materials Agilent Atomic Spectroscopy Solutions USP <232>/<233> & ICH Q3D(R2)/Q2(R1) Implementing Elemental Impurities Tests in the Pharmaceutical Industry Worldwide regulations for pharmaceutical materials Worldwide pharmacopeias have introduced revised standards for controlling elemental impurities in drug…